Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins

Pediatric Pulmonology

Volumn 48, Issue 2, 2013, Pages 107-122

  Zobell, Jeffery T ^a,b   Waters, C Dustin ^c   Young, David C ^d,e   Stockmann, Chris ^f   Ampofo, Krow ^f   Sherwin, Catherine M T ^f   Spigarelli, Michael G ^f  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b Intermountain Cystic Fibrosis Pediatric Center   (United States)

^c McKay Dee Hospital Center   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Intermountain Cystic Fibrosis Adult Center   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

beta lactams; pharmacodynamics; pharmacokinetics; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; CARBENICILLIN; CARBOXYPENICILLIN PLUS TICARCILLIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG; UREIDOPENICILLIN PLUS PIPERACILLIN;

ABDOMINAL PAIN; ACUTE PULMONARY EXACERBATION; ALLERGIC REACTION; ANAPHYLAXIS; ANOREXIA; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; EOSINOPHILIA; ERYTHEMA; FEVER; HEADACHE; HEMATURIA; HEMOPTYSIS; HUMAN; HYPOKALEMIA; INJECTION SITE PAIN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MALAISE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; PHARYNGITIS; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RASH; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT DISEASE; SIDE EFFECT; THROMBOCYTOPENIA; TONSILLITIS; UREA NITROGEN BLOOD LEVEL; URTICARIA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CEFTAZIDIME; CEPHALOSPORINS; CLAVULANIC ACIDS; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TICARCILLIN;

EID: 84872404132     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22669     Document Type: Article

References (75)

1. Ramsey BW,. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996; 335: 179-188.
2. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC,. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009; 180: 802-808.
3. Zobell JT, Young DC, Waters CD, Ampofo K, Cash J, Marshall BC, Olson J, Chatfield BA,. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients. Pediatr Pulmonol 2011; 46: 987-990.
4. Van Meter DJ, Corriveau M, Ahern JW, Lahiri T,. A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis. Pediatr Pulmonol 2009; 44: 325-329.
5. Petri WA,. Antimicrobial agents: penicillins, cephalosporins, and other beta-lactam antibiotics. In:, Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. pp 1189-1218.
6. Fortaz® Approved Package labeling 2010, GlaxoSmithKline.
7. Drug Information Handbook, 2011, Lexi-Comp, Inc.
8. Pediatric Dosage Handbook, 2011, Lexi-Comp, Inc.
9. Maxipime® Approved Package lableling, 2009, Bristol Meyers Squibb.
10. Burgess DS,. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005; 40: S99-S104.
11. Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
12. Burgess DS, Hastings RW, Hardin TC,. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22: 66-75.
13. Drusano GL,. Antimicrobial pharmacodynamics: critical interactions of "bug and drug. " Nat Rev Microbiol 2004; 2: 289-300.
14. Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, Blumer JL,. Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother 1983; 12: 289-295.
15. Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, Assael BM, Granata F, Passarella E, Vallaperta PA, Xerri L,. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. J Pediatr 1983; 103: 320-324.
16. Strandvik B, Malmborg AS, Alfredson H, Ericsson A,. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother 1983; 12: 283-287.
17. Turner A, Pedler SJ, Carswell F, Spencer GR, Speller DC,. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother 1984; 14: 521-527.
18. Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, MacLeod SM,. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther 1984; 36: 355-362.
19. Munzenberger PJ, Hsu JM, Holliday SJ,. Relationship of ceftazidime pharmacokinetic indices with therapeutic outcome in patients with cystic fibrosis. Pediatr Infect Dis 1993; 12: 997-1001.
20. Testing, E.C.o.A.S. Breakpoint tables for interpretation of MICs and zone diameters, 2011, EUCAST.
21. Institute, C.a.L.S. Performance standards for antimicrobial susceptibility testing: twenty-first international supplement M 100-S21. Wayne, PA: CLSI; 2011.
22. Hedman A, Adan-Abdi Y, Alvan G, Strandvik B, Arvidsson A,. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clin Pharmacokinet 1988; 15: 57-65.
23. Vinks AA, Mouton JW, Touw DJ, Heijerman HG, Danhof M, Bakker W,. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 1996; 40: 1091-1097.
24. Mouton JW, Punt N, Vinks AA,. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005; 27: 762-772.
25. Bulitta JB, Landersdorfer CB, Huttner SJ, Drusano GL, Kinzig M, Holzgrabe U, Stephan U, Sorgel F,. Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2010; 54: 1275-1282.
26. Nicolau DP, Nightingale CH, Banevicius MA, Fu Q, Quintiliani R,. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40: 61-64.
27. Hamelin BA, Moore N, Knupp CA, Ruel M, Vallee F, LeBel M,. Cefepime pharmacokinetics in cystic fibrosis. Pharmacotherapy 1993; 13: 465-470.
28. Huls CE, Prince RA, Seilheimer DK, Bosso JA,. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993; 37: 1414-1416.
29. Arguedas AG, Stutman HR, Zaleska M, Knupp CA, Marks MI, Nussbaum E,. Cefepime. Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child 1992; 146: 797-802.
30. Prince AS, Neu HC,. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. J Pediatr 1980; 97: 148-151.
31. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL,. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 1987; 3: 101-109.
32. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, Halsey NA,. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatr Pulmonol 1988; 4: 201-204.
33. Hoogkamp-Korstanje JA, van der Laag J,. Piperacillin and tobramycin in the treatment of pseudomonas lung infections in cystic fibrosis. J Antimicrob Chemother 1983; 12: 175-183.
34. Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sorgel F,. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother 2007; 51: 2497-2507.
35. Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD,. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis 1986; 5: 440-443.
36. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW,. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob Agents Chemother 2003; 47: 541-547.
37. Jacobs RF, Trang JM, Kearns GL, Warren RH, Brown AL, Underwood FL, Kluza RB,. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. J Pediatr 1985; 106: 1001-1007.
38. de Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL,. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther 1990; 47: 73-78.
39. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K,. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther 2011; 33: 1844-1850.
40. Foundation CF,. Microbiology and Infectious Disease in Cystic Fibrosis. In Cystic Fibrosis Foundation Consensus Conference. 1994.
41. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, Touw DJ,. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000; 16: 749-767.
42. Blumer JL, Saiman L, Konstan MW, Melnick D,. The efficacy and safety of meropenem and tobramycin vs. ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005; 128: 2336-2346.
43. Byrne S, Maddison J, Connor P, Doughty I, Dodd M, Jenney M, Webb AK, David TJ,. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995; 36: 135-143.
44. Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, Moller S,. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother 1983; 12: 313-323.
45. Reed MD, Stern RC, O'Brien CA, Crenshaw DA, Blumer JL,. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis. Antimicrob Agents Chemother 1987; 31: 698-702.
46. Salh B, Bilton D, Dodd M, Abbot J, Webb K,. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand J Infect Dis 1992; 24: 215-218.
47. Schaad UB, Wedgwood-Krucko J, Guenin K, Buehlmann U, Kraemer R,. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur J Clin Microbiol Infect Dis 1989; 8: 858-865.
48. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, Grenet D, Sermet-Gaudelus I, Ramel S, Cracowski C,. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53: 3650-3656.
49. Latzin P, Fehling M, Bauernfeind A, Reinhardt D, Kappler M, Griese M,. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros 2008; 7: 142-146.
50. Zosyn® Approved Package labeling 2009; Wyeth.
51. De Boeck K, Smet M, Eggermont E,. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication. Pediatr Pulmonol 1989; 7: 171-173.
52. Reichardt P, Handrick W, Linke A, Schille R, Kiess W,. Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment-a retrospective analysis in 38 children with cystic fibrosis. Infection 1999; 27: 355-356.
53. Stead RJ, Kennedy HG, Hodson ME, Batten JC,. Adverse reactions to piperacillin in adults with cystic fibrosis. Thorax 1985; 40: 184-186.
54. Kunzmann S, Thomas W, Mayer B, Kuhn S, Hebestreit H,. Immune-mediated severe hemolytic crisis with a hemoglobin level of 1.6 g/dl caused by anti-piperacillin antibodies in a patient with cystic fibrosis. Infection 2010; 38: 131-134.
55. Thickett KM, Wildman MJ, Fegan CD, Stableforth DE,. Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis. J Antimicrob Chemother 1999; 43: 435-436.
56. Bandara M, Seder DB, Garratty G, Leger RM, Zuckerman JB,. Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis. Case Rep Med 2010; 2010: 161454.
57. Chavez A, Mian A, Scurlock AM, Blackall D, Com G,. Antibiotic hypersensitivity in CF: drug-induced life-threatening hemolytic anemia in a pediatric patient. J Cyst Fibros 2010; 9: 433-438.
58. Moller NE, Eriksen KR, Feddersen C, Flensborg EW, Hoiby N, Norn S, Rosendal K, Schiotz PO, Skov PS,. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin. Eur J Respir Dis 1982; 63: 130-139.
59. Macfarlane PI, Hughes DM, Landau LI, Olinsky A,. The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study. Pediatr Pulmonol 1985; 1: 249-255.
60. Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP,. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Transfusion 2012; 52: 4-5.
61. Timentin® Approved Package labeling, 2010, GlaxoSmitKline.
62. Zobell JT, Ampofo K, Cash J, Korgenski K, Chatfield BA,. High dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. J Cyst Fibros 2010; 9: 280-283.
63. Parry MF, Neu HC,. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. J Infect Dis 1976; 134: S194-S197.
64. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR,. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr 1977; 90: 144-148.
65. Penketh AR, Hodson ME, Batten JC,. Ticarcillin compared with carbenicillin in the treatment of exacerbations of bronchopulmonary infection in cystic fibrosis. Br J Dis Chest 1983; 77: 179-184.
66. Horrevorts AM, de Witte J, Degener JE, Dzoljic-Danilovic G, Hop WC, Driessen O, Michel MF, Kerrebijn KF,. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest 1987; 92: 844-848.
67. Conway SP, Miller MG, Ramsden C, Littlewood JM,. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Acta Paediatr Scand 1985; 74: 107-113.
68. Schaad UB, Desgrandchamps D, Kraemer R,. Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin. Acta Paediatr Scand 1986; 75: 128-138.
69. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM,. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-127.
70. Trust UCF,. Antibiotic Treatment for Cystic Fibrosis. in UK Cystic Fibrosis Trust Antibiotic Working Group. 2009.
71. Alou L, Aguilar L, Sevillano D, Gimenez MJ, Echeverria O, Gomez-Lus ML, Prieto J,. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 2005; 55: 209-213.
72. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, Claass A, Broemme S, Jeschke R, Hebestreit A,. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009; 37: 418-423.
73. Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH,. Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 127-134.
74. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH,. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 627-632.
75. Zobell JT, Stockmann C, Young DC, Cash J, McDowell BJ, Korgenski K, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo K,. Population pharmacokinetic and pharmacodynamic modeling of high dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther 2011; 33: 1844-1850.